News & media
-
Resolutions from Zealand Pharma's Extraordinary General Meeting 2026
-
Zealand Pharma - Transactions related to share buy-back program (weeks 19-20, 2026)
-
Zealand Pharma - Execution framework for share buy-back program
-
Zealand Pharma Announces Financial Results for the First Three Months of 2026
-
Zealand Pharma initiates USD 200 million / DKK 1.3 billion share buy-back program
-
The Zealand Pharma Board of Directors proposes to elect Camilla Sylvest to the Board of Directors at an upcoming Extraordinary General Meeting
-
Zealand Pharma convenes Extraordinary General Meeting on May 26, 2026
-
Zealand Pharma conference call on May 7 at 2pm CET (8am ET) to present first quarter 2026 financial results
-
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
-
Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
-
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
-
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Corporate management
-
Adam Steensberg - President and Chief Executive Officer
-
Adam Steensberg - President and Chief Executive Officer
-
Adam Steensberg - President and Chief Executive Officer
-
Henriette Wennicke - Executive Vice President and Chief Financial Officer
-
Christina Sonnenborg Bredal - Executive Vice President and Chief People Officer
-
David Kendall - Executive Vice President, Research & Development and Chief Medical Officer
-
Ivan Møller - Executive Vice President and Chief Operating Officer
-
Utpal Singh - Executive Vice President and Chief Scientific Officer
-
Utpal Singh - Executive Vice President and Chief Scientific Officer
-
Steven Johnson - Executive Vice President, Chief Development Officer
-
Eric Cox - Executive Vice President, Chief Commercial Officer
Research and development
-
Lab photo
-
Lab photo
-
Lab photo
-
Lab photo
-
Lab photo
-
Lab photo
-
Lab photo
Sustainability
-
Morten Lagstrøm - ESG Officer
Logos and icons
-
)
Zealand Pharma Logo (RGB)
Stay up-to-date with the latest news from Zealand
Sign-up to receive press releases and company announcements directly to your inbox
Investor and Media contacts
